Pangaea Oncology S.A.
Pangaea Oncology, S.A., a medical services company, provides a range of services to cancer patients in Spain and the rest of European Union countries. It offers molecular diagnostics, such as mutation analysis in tissue and liquid biopsy, gene amplification and translocation testing, immunohistochemistry and fluorescence in-situ hybridization, and gene expression profiling; clinical trials; in vi… Read more
Pangaea Oncology S.A. (PANG) - Net Assets
Latest net assets as of June 2025: €21.14 Million EUR
Based on the latest financial reports, Pangaea Oncology S.A. (PANG) has net assets worth €21.14 Million EUR as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€29.57 Million) and total liabilities (€8.43 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €21.14 Million |
| % of Total Assets | 71.49% |
| Annual Growth Rate | 25.81% |
| 5-Year Change | 166.59% |
| 10-Year Change | 2068.37% |
| Growth Volatility | 136.96 |
Pangaea Oncology S.A. - Net Assets Trend (2013–2024)
This chart illustrates how Pangaea Oncology S.A.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Pangaea Oncology S.A. (2013–2024)
The table below shows the annual net assets of Pangaea Oncology S.A. from 2013 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €22.84 Million | +21.42% |
| 2023-12-31 | €18.81 Million | -18.49% |
| 2022-12-31 | €23.08 Million | +63.83% |
| 2021-12-31 | €14.09 Million | +64.42% |
| 2020-12-31 | €8.57 Million | +3.03% |
| 2019-12-31 | €8.31 Million | -3.50% |
| 2018-12-31 | €8.62 Million | +70.67% |
| 2017-12-31 | €5.05 Million | -16.51% |
| 2016-12-31 | €6.05 Million | +474.15% |
| 2015-12-31 | €1.05 Million | -35.32% |
| 2014-12-31 | €1.63 Million | -10.84% |
| 2013-12-31 | €1.83 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Pangaea Oncology S.A.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 17305.1% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | €688.29K | 3.11% |
| Other Components | €34.73 Million | 157.13% |
| Total Equity | €22.10 Million | 100.00% |
Pangaea Oncology S.A. Competitors by Market Cap
The table below lists competitors of Pangaea Oncology S.A. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Manx Financial Group PLC
F:3IM
|
$13.98 Million |
|
Nuriplan Co. Ltd
KQ:069140
|
$13.98 Million |
|
PesoRama Inc.
PINK:PSSOF
|
$13.98 Million |
|
Compañía Minera Autlán S.A.B. de C.V
MX:AUTLANB
|
$13.99 Million |
|
Kyoritsu Electric Corporation
MU:KYO
|
$13.96 Million |
|
PlumbFast Co. Ltd
KQ:035200
|
$13.96 Million |
|
Chemfab Alkalis Limited
NSE:CHEMFAB
|
$13.96 Million |
|
Siam Steel Service Center Public Company Limited
BK:SSSC
|
$13.96 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Pangaea Oncology S.A.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 17,824,006 to 22,104,695, a change of 4,280,689 (24.0%).
- Net loss of 1,166,587 reduced equity.
- Share repurchases of 159,220 reduced equity.
- Other comprehensive income decreased equity by 991,428.
- Other factors increased equity by 6,597,924.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-1.17 Million | -5.28% |
| Share Repurchases | €159.22K | -0.72% |
| Other Comprehensive Income | €-991.43K | -4.49% |
| Other Changes | €6.60 Million | +29.85% |
| Total Change | €- | 24.02% |
Book Value vs Market Value Analysis
This analysis compares Pangaea Oncology S.A.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.27x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 9.73x to 2.27x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-12-31 | €0.17 | €1.65 | x |
| 2014-12-31 | €0.15 | €1.65 | x |
| 2015-12-31 | €0.10 | €1.65 | x |
| 2016-12-31 | €0.56 | €1.65 | x |
| 2017-12-31 | €0.47 | €1.65 | x |
| 2018-12-31 | €0.65 | €1.65 | x |
| 2019-12-31 | €0.49 | €1.65 | x |
| 2020-12-31 | €0.45 | €1.65 | x |
| 2021-12-31 | €0.62 | €1.65 | x |
| 2022-12-31 | €0.76 | €1.65 | x |
| 2023-12-31 | €0.59 | €1.65 | x |
| 2024-12-31 | €0.73 | €1.65 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Pangaea Oncology S.A. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -5.28%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -8.18%
- • Asset Turnover: 0.44x
- • Equity Multiplier: 1.47x
- Recent ROE (-5.28%) is above the historical average (-19.82%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 4.24% | 2.51% | 0.47x | 3.58x | €-105.23K |
| 2014 | -12.06% | -11.44% | 0.20x | 5.20x | €-359.23K |
| 2015 | -46.18% | -24.95% | 0.18x | 10.45x | €-591.68K |
| 2016 | -9.83% | -23.61% | 0.14x | 2.97x | €-1.20 Million |
| 2017 | -32.62% | -62.82% | 0.14x | 3.75x | €-2.15 Million |
| 2018 | -14.54% | -40.96% | 0.15x | 2.36x | €-2.11 Million |
| 2019 | -58.22% | -145.96% | 0.20x | 2.03x | €-5.67 Million |
| 2020 | -20.95% | -43.77% | 0.24x | 2.00x | €-2.65 Million |
| 2021 | -4.56% | -13.94% | 0.22x | 1.48x | €-2.05 Million |
| 2022 | -11.75% | -62.09% | 0.15x | 1.23x | €-5.02 Million |
| 2023 | -26.12% | -58.22% | 0.28x | 1.62x | €-6.44 Million |
| 2024 | -5.28% | -8.18% | 0.44x | 1.47x | €-3.38 Million |
Industry Comparison
This section compares Pangaea Oncology S.A.'s net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $51,463,471
- Average return on equity (ROE) among peers: 21.59%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Pangaea Oncology S.A. (PANG) | €21.14 Million | 4.24% | 0.40x | $13.97 Million |
| Clinica Baviera (CBAV) | $98.36 Million | 40.88% | 1.15x | $110.76 Million |
| Euroespes S.A. (EEP) | $4.57 Million | 2.31% | 1.05x | $3.02 Million |